Fortress Biotech Announces Publication on MB-101 for the Treatment of Glioblastoma in New England Journal of Medicine NEW YORK, Dec. 28, 2016 — Fortress Biotech, Inc. , a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that a patient case study from the Phase 1 clinical trial of MB-101 for the treatment of glioblastoma will be published in the December 29 edition of the New England Journal of Medicine. MB-101 is the lead development candidate of Mustang Bio, Inc., a Fortress Company.